Non-Hodgkin Lymphoma | Specialty

Clinical Trials of CAR T-Cell Therapy in NHL

October 29th 2018

Clinical Data Surrounding CAR T-Cell Therapy in NHL

October 29th 2018

CAR T-Cell Therapies for Relapsed/Refractory NHL

October 29th 2018

Unmet Needs in Treating Relapsed NHL

October 29th 2018

Traditional Therapies for High-Risk Lymphoma and Efficacy

October 29th 2018

FDA Grants Priority Review to Ibrutinib Plus Obinutuzumab in Frontline CLL

October 17th 2018

The FDA has granted a priority designation to a supplemental new drug application for ibrutinib for use in combination with obinutuzumab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Kaplan on the RELEVANCE Trial in Follicular Lymphoma

October 9th 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.

Capitalizing on Promise of CAR T Cells in DLBCL

October 5th 2018

Charalambos (Babis) Andreadis, MD, MSCE, discusses the use of CAR T-cell therapy in patients with DLBCL and the associated toxicities with each product, as well as other promising therapies in the paradigm.

Brentuximab Vedotin Improves Survival in Frontline CD30+ PTCL

October 2nd 2018

Combining brentuximab vedotin with frontline chemotherapy led to a statistically significant improvement in progression-free and overall survival in patients with CD30-expressing peripheral T-cell lymphoma, according to topline results from the phase III ECHELON-2 trial.

Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma

September 25th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

FDA Approves Duvelisib for CLL and Follicular Lymphoma

September 25th 2018

The FDA has approved duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma.

Ongoing Trials Hope to Move DLBCL Field Beyond R-CHOP

September 15th 2018

Cure rates in diffuse large B-cell lymphoma remain relatively unchanged, even following therapeutic additions to the armamentarium and an improved understanding of disease biology.

Dr. Locke on Bridging Chemotherapy in Patients With Non-Hodgkin Lymphoma

September 13th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of bridging chemotherapy in patients receiving chimeric antigen receptor (CAR) T-cell therapy.

Clear Guidelines Needed for CNS Involvement in Lymphoma

September 13th 2018

Philip Bierman, MD, discusses the current landscape of central nervous system involvement in aggressive lymphoma and the research that should be conducted.

Dr. Locke on CAR T-Cell Therapy in NHL

September 10th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with non–Hodgkin lymphoma (NHL).

Dr. Kahl Discusses the Construction of ADCs for Lymphoma Treatment

September 6th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the construction of antibody-drug conjugates for the treatment of patients with lymphoma.

Dr. Smith Advises Clinicians on Diagnosing Double-Hit and Triplet-Hit Lymphoma

September 6th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.

Regimens Emerging Beyond Chemo in Follicular Lymphoma

September 6th 2018

Celeste Bello, MD, discusses the latest advances in the treatment of patients with follicular lymphoma.

Dr. Locke Discusses Unanswered Questions With CAR T-Cell Therapy

September 5th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor T-cell therapy.

Expert Discusses Latest CAR T-Cell Developments in Non-Hodgkin Lymphoma

September 5th 2018

David G. Maloney, MD, PhD, reviews the latest developments with chimeric antigen receptor T-cell therapy in patients with non-Hodgkin lymphoma.